Zobrazeno 1 - 10
of 107
pro vyhledávání: ''
Autor:
Juliann E. Kosovec, Laila Babar, Shahin Ayazi, Gene Grant Finley, Ali H. Zaidi, Soyoung Lee, Blair A. Jobe, Ashten N. Omstead, Madison Salvitti, Ronan J. Kelly, Ping Zheng, Ajay Goel, Anastasia Gorbunova
Publikováno v:
Oncotarget
Background: Esophageal adenocarcinoma (EAC) is a deadly disease with limited treatment options. STING is a transmembrane protein that activates transcription of interferon genes, resulting in stimulation of APCs and enhanced CD8+ T-cell infiltration.
Autor:
Calabrese Angela, Licchetta Antonella, Longo Vito, Argentiero Antonel-la, Brunetti Oronzo, Calbi Roberto, Gnoni Antonio, Solimando Antonio Giovanni
Publikováno v:
Oncotarget
Osteoimmunology was coined about twenty years ago to identify a strict cross talk between bone niche and immune system both in physiological and pathological activities, including cancer. Several molecules are involved in the complex interaction betw
Autor:
Ashok Sharma, Ritu Gupta, Neerja Bhatla, Sunesh Kumar, Lalit Kumar, Minakshi Mann, Sachin Kumar, Sameer Bakhshi, Shyam S. Chauhan
Publikováno v:
Oncotarget
Cisplatin is a keystone for treatment of both recurring and locally advanced cervical cancer. However toxic side effects and acquired resistance limits its efficacy. Enhanced DNA repair is one of the mechanisms through which cancer cells acquire cisp
Publikováno v:
Oncotarget
Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) mutation benefit from a first line of treatment with tyrosine kinase inhibitors (TKIs). After progression, the choice of treatment is between chemotherapy and im
Autor:
Yuta Kaito, Yoichi Imai, Yasuko Kuribayashi, Mika Sunakawa, Saori Soeda, Mariko Ishibashi, Asaka Onodera, Yutaka Tsukune, Toshio Asayama, Junji Tanaka, Norina Tanaka, Hiroshi Handa, Makoto Sasaki, Koiti Inokuchi, Sakae Tanosaki, Hideto Tamura, Takeshi Odajima, Keiichi Moriya, Shigeki Ito, Norio Komatsu, Hiroki Sugimori, Ryosuke Kinoshita
Publikováno v:
Oncotarget
The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The ob
Autor:
Sven Golfier, Dominik Mumberg, Sabine Zitzmann-Kolbe, Karl Ziegelbauer, Cem Elbi, Christoph A. Schatz, Urs B. Hagemann, Beatrix Stelte-Ludwig, Maria Quanz
Publikováno v:
Oncotarget
Despite the recent advances in the treatment of ovarian cancer, it remains an area of high unmet medical need. Epithelial ovarian cancer is associated with high levels of mesothelin expression, and therefore, mesothelin is an attractive candidate tar
Autor:
Shuhei Suzuki, Hiroyuki Takeda, Kenta Kuramoto, Chifumi Kitanaka, Keita Togashi, Takashi Yoshioka, Masahiro Yamamoto, Shizuka Seino, Tomomi Sanomachi, Masashi Okada
Publikováno v:
Oncotarget
// Shuhei Suzuki 1, 2 , Masashi Okada 1 , Hiroyuki Takeda 1, 2 , Kenta Kuramoto 1 , Tomomi Sanomachi 1, 2 , Keita Togashi 1, 3 , Shizuka Seino 1, 4 , Masahiro Yamamoto 1 , Takashi Yoshioka 2 and Chifumi Kitanaka 1, 4 1 Department of Molecular Cancer
Autor:
Alejandro Morales-Restrepo, Kavita Ramnath, Jared A. Crasto, Kurt R. Weiss, Rebecca J. Watters, Jessica C. Tebbets, Jonathan B. Mandell, Adel Mahjoub, Mitchell S. Fourman
Publikováno v:
Oncotarget
// Jared Anthony Crasto 1, * , Mitchell Stephen Fourman 1, * , Alejandro Morales-Restrepo 1 , Adel Mahjoub 1, 2 , Jonathan Brendan Mandell 1 , Kavita Ramnath 1, 3 , Jessica C. Tebbets 1 , Rebecca J. Watters 1, 4 and Kurt Richard Weiss 1, 5 1 Musculos
Autor:
Hanna Voropaev, Maria Gimmelshein, Nathalie Cassoux, Dudi Shneor, Shay Tayeb, Alik Honigman, Shahar Frenkel, Jacob Pe'er
Publikováno v:
Oncotarget
Uveal melanoma (UM) is the most frequent intraocular tumor in adult patients. When metastases occur, systemic therapy with alkylating agents (fotemustine or dacarbazine (DTIC)) has shown only modest efficacy. The common chemotherapeutic drug doxorubi
Publikováno v:
Oncotarget
The quest for new and improved therapies for glioblastoma (GB) has been mostly unsuccessful in more than a decade despite significant efforts. The few exceptions include the optimization of classical alkylating chemotherapy by including lomustine in